NCT06568952Completed
Right Ventricular Function in Patients Taking Carfilzomib
Right Ventricular Function of Patients With Multiple Myeloma Treated With Carfilzomib
Source: ClinicalTrials.gov · Last updated 23 Aug 2024
Brief summary (registry, in English)
Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension. This is well documented in the literature. However, there are no studies looking at right ventricular function in these patients, both before and during treatment.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 36 (actual)
- First submitted
- 20 Aug 2024
- Start date
- 30 Apr 2024
- Primary completion date
- 30 Jun 2024
- Lead sponsor
- Central Hospital, Nancy, France
- NCT number
- NCT06568952
What you commit to
- Study type: Observational
- Participants enrolled: 36
- From 30 Apr 2024 to the primary completion date, 30 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- /
Who the study is looking for
- Patients treated for multiple myeloma with carfilzomib
- Patients with echocardiogram before and under treatment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Simon VALENTIN Coordinator of this site? Confirm its status | Nancy | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.